Spexis Ltd

Spexis Ltd

Spexis Ltd was founded in 2021 by Jeff Wager through a reverse merger of Enbiotix Inc. (which Wager co-founded in 2013) and Polyphor AG. The firm operates from Allschwil, Switzerland, with a stated focus on intelligent macrocycle design — an approach combining small-molecule advantages with antibody-like specificity. The firm's strategy centers on macrocycle therapeutics, a class that targets undruggable proteins. Spexis develops candidates across infectious disease and oncology, leveraging proprietary platforms for macrocycle discovery and optimization. The company has not publicly disclosed specific portfolio holdings, but its pipeline aligns with the broader macrocycle space, which includes validated targets like PD-L1 and RAS. Wager's prior transactions include building Grupo Biotoscana SL ($1B IPO) and Artisan Pharma (acquired by Asahi Kasei in 2011). Spexis disclosed no AUM or deployment numbers. The firm employs a lean structure typical of early-stage biotech, with Wager as the only named principal. No additional offices or philanthropic vehicles are publicly documented. Wager's track record includes raising $53M for Artisan Pharma and advising Zambon Group's €60M corporate venture fund. A structural differentiator: Spexis uses a reverse-merger model to enter public markets without a traditional IPO, combining existing platforms (Polyphor) with new leadership. This gives the firm a built-in pipeline and exchange listing from inception — a cost-efficient path to drug development that contrasts with venture-backed startups.